Yes, osteogenesis imperfecta (OI) is a genetic condition. It results from mutations in genes responsible for producing or processing type I collagen, the main structural protein in bone, skin, and connective tissue. OI affects roughly 1 in every 16,000 to 20,000 births, and the genetic changes responsible can be either inherited from a parent or arise spontaneously for the first time in a child with no family history of the condition.
The Genes Behind OI
The vast majority of OI cases trace back to mutations in two genes called COL1A1 and COL1A2. These genes carry the instructions for building the two types of protein chains that wind together to form type I collagen. A finished collagen molecule is a triple helix made of two alpha-1 chains and one alpha-2 chain, twisted tightly like a three-stranded rope. Every third amino acid in this rope must be glycine, the smallest amino acid, because only glycine is small enough to fit inside the tightly wound center of the helix.
When a mutation disrupts this process, the consequences depend on how the collagen is affected. There are two broad categories:
- Quantitative defects (less collagen, normal structure): The body produces about half the normal amount of structurally sound collagen. This typically happens when a mutation in COL1A1 shuts down one copy of the gene through premature stop signals in the genetic code. The result is milder OI, often classified as Type I, with bones that fracture more easily but generally maintain their shape.
- Qualitative defects (abnormal collagen structure): A mutation swaps out one of those critical glycine amino acids for a larger one, which jams the folding process. The collagen that does get made is structurally flawed. This leads to moderate-to-severe forms of OI, including types that cause progressive bone deformity or are lethal before or shortly after birth.
Where the mutation falls along the gene also matters. Because the collagen triple helix assembles starting from one end and zipping toward the other, mutations near the starting end of assembly tend to cause more severe disease. Mutations near the opposite end often produce milder symptoms.
Dominant vs. Recessive Inheritance
Most OI follows an autosomal dominant pattern, meaning a mutation in just one copy of the gene is enough to cause the condition. If one parent has OI caused by a dominant mutation, each pregnancy carries a 50% chance of passing it on. The dominant forms are caused by direct defects in the collagen genes themselves.
A smaller group of cases, accounting for fewer than 5% of all OI diagnoses, follows an autosomal recessive pattern. Recessive OI requires a child to inherit a faulty copy of the same gene from both parents. These mutations don’t occur in the collagen genes directly. Instead, they affect helper proteins that modify and fold collagen after it’s made. Two of the best-studied examples are proteins called CRTAP and P3H1, which work together as a complex to chemically modify a specific spot on the collagen chain. When either protein is missing, the collagen that results is poorly processed, leading to severe OI with multiple fractures, extremely low bone density, and abnormal bone modeling, particularly in the thighbones.
Because carriers of recessive OI mutations have no symptoms and no family history of brittle bones, these cases can seem to appear out of nowhere. Each future pregnancy for the same parents carries a 25% chance of producing another affected child.
Spontaneous Mutations Are Common
A striking feature of OI is how often it occurs without any family history at all. Research estimates that 35% to 60% of OI cases result from de novo mutations, meaning the genetic change happened for the first time in the affected person rather than being passed down. One study analyzing collagen-related OI found that 56% of cases were de novo.
This is an important point for families who have never seen OI in their relatives. A child can be born with brittle bones even when neither parent carries the mutation in their own cells. However, once a de novo mutation has occurred, the person who carries it can pass it on to their children following the standard dominant inheritance pattern.
There is one additional genetic wrinkle. Some parents who appear unaffected actually carry the OI mutation in a fraction of their egg or sperm cells but not in the rest of their body. This is called gonadal mosaicism, and it explains why, for the most severe form of OI (Type II, which is often lethal around birth), there is a 2% to 7% recurrence risk in future pregnancies even when neither parent shows any signs of the condition.
The Five Clinical Types
OI is traditionally grouped into five types based on severity and clinical features, a system originally developed by David Sillence in the 1970s and refined since.
Type I is the mildest and most common form. It results from reduced production of normal collagen, usually due to COL1A1 mutations. People with Type I typically have blue-tinged whites of the eyes, fracture more easily during childhood, and may experience hearing loss in adulthood, but they generally have near-normal stature and minimal bone deformity.
Type II is the most severe form and is usually lethal around the time of birth. It was once thought to be recessive but is now recognized as a dominant-negative disorder, most often caused by spontaneous mutations that produce severely abnormal collagen.
Type III is the most severe form compatible with survival. It causes progressive bone deformity, very short stature, and frequent fractures. It can result from either dominant collagen gene mutations or recessive mutations in helper-protein genes.
Type IV is a moderate form with variable severity. Bones fracture easily and some bowing may develop, but the whites of the eyes are typically normal in color. It follows autosomal dominant inheritance.
Type V stands apart because it is not caused by a collagen gene mutation at all. Instead, it results from a mutation in a gene called IFITM5 and produces a distinctive pattern that includes calcification of the membranes between the forearm bones. It is autosomal dominant.
Beyond these five, researchers have identified additional rare types (numbered VI through XI and higher) linked to mutations in over a dozen different genes. The international skeletal disorders community updated its naming system in 2023, moving toward pairing each clinical presentation with the specific gene responsible, which reduces confusion from the growing list of numbered types.
How OI Is Genetically Diagnosed
If OI is suspected based on a pattern of unexplained fractures, family history, or physical features like blue sclerae, genetic testing can confirm the diagnosis. The primary approach is DNA sequencing of COL1A1 and COL1A2, which identifies mutations in the majority of cases. When those genes come back normal, expanded panels test the rarer genes associated with recessive forms.
An older method involves growing skin cells (fibroblasts) from a biopsy and measuring how much collagen they produce and whether its structure is normal. This biochemical approach can distinguish between quantitative defects (reduced but normal collagen, pointing to Type I) and qualitative defects (structurally abnormal collagen, pointing to more severe forms).
Prenatal testing is available for families with a known mutation. DNA from a chorionic villus sample can be analyzed in about one to two weeks if the specific family mutation has already been identified. Biochemical collagen testing on chorionic villus cells is also possible for Types II, III, and IV, though results take about three to four weeks. Biochemical prenatal testing cannot reliably detect Type I because the reduced-but-normal collagen production characteristic of that type isn’t detectable in placental cells.